We will be comparing the differences between Therapix Biosciences Ltd. (NASDAQ:TRPX) and Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) as far as institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Therapix Biosciences Ltd.	N/A	0.00	7.71M	-2.12	0.00
Navidea Biopharmaceuticals Inc	1.17M	20.57	16.17M	-0.12	0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Therapix Biosciences Ltd. and Navidea Biopharmaceuticals Inc.

Profitability

Table 2 represents Therapix Biosciences Ltd. (NASDAQ:TRPX) and Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Therapix Biosciences Ltd.	0.00%	0%	0%
Navidea Biopharmaceuticals Inc	-1,382.05%	-355.9%	-119.6%

Insider & Institutional Ownership

Institutional investors held 0% of Therapix Biosciences Ltd. shares and 5.5% of Navidea Biopharmaceuticals Inc shares. About 2.08% of Therapix Biosciences Ltd.’s share are held by insiders. Comparatively, insiders own roughly 12.3% of Navidea Biopharmaceuticals Inc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Therapix Biosciences Ltd.	10.12%	25.81%	-18.04%	5.64%	-14.6%	44%
Navidea Biopharmaceuticals Inc	1.15%	1.95%	-14.36%	-4.02%	-53.27%	62.68%

For the past year Therapix Biosciences Ltd. has weaker performance than Navidea Biopharmaceuticals Inc

Summary

Navidea Biopharmaceuticals Inc beats Therapix Biosciences Ltd. on 5 of the 9 factors.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, San Diego. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.